Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors
申请人:PFIZER INC.
公开号:US11220518B2
公开(公告)日:2022-01-11
The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B:
wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.
本发明涉及式 A 和 B 的化合物和药学上可接受的盐:
其中A、B、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如上所定义。本发明进一步涉及包含本发明化合物和药学上可接受的盐的药物组合物,以及治疗糖尿病及其并发症、癌症、缺血、炎症、中枢神经系统疾病、心血管疾病、阿尔茨海默病和皮肤病压迫、病毒性疾病、炎症性疾病或以肝脏为靶器官的疾病的方法。